Google
Trusted Resources: Community Center
Online groups, photo galleries and blogs
Pioneering a New Therapy for Sickle Cell Disease
The science behind sickle cell disease (SCD) is cruel. For approximately 100,000 American children and adults (and 10-15 million people around the globe), a mutation in a single gene means a lifetime of unpredictable and excruciating pain—along with exhaustion, serious infections, and collateral damage to the brain, heart, lungs, and other organs. Anemia, strokes, pregnancy problems, kidney disease, and joint pain are common.
But the racial inequities that have hindered treatment advances for SCD—the most common inherited blood disorder in the United States—are far crueler. “I was at a conference recently where an older woman stood up and said she’d been in situations where she was effectively told, ‘Sickle cell disease is an
African-American problem. It’s up to you guys to solve it,’ ” says physician Ted W. Love ’81, M.D., CEO of Global Blood Therapeutics (GBT) in South San Francisco. “But there’s no reason the greater society as a whole shouldn’t be solving this. And thankfully we’re starting to see it get the attention it deserves these days across the biotech industry and with drug regulators.”
+myBinderRelated Content
-
Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow TransplantObjective: A comparative cost analysis o...
-
Acceptability of In Utero Hematopoietic Cell Transplantation for Sickle Cell DiseaseBACKGROUND: In utero hematopoietic cell ...
-
Blood Transfusions: What You Need to Know and Do (Part 2: Blood Matching)https://www.youtube.com/watch?v=bs4bRApy...
-
Gene Therapy for Blood DisordersIn the context of intense scrutiny over ...
-
100 Years But Only One Drug: Sickle Cell Patients Wait For HelpLast week, 100,000 Americans with sickle...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Calimmune Expands Lentiviral Gene Therapy Pipeline Through License of Sickle Cell Disease Therapeutic CandidateLicense of Gamma-Globin from Cincinnati ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
